Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.51 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | MAP2 | P11137 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7727169 | 0.99 | LMNA (0.57) | LMNARECQLPTGS2NISCHHTR6 | |
| SCHEMBL6824740 | 0.94 | LMNA (0.48) | LMNARECQLPTGS2NISCHHTR6 | |
| SCHEMBL6825016 | 0.92 | NISCH (0.51) | LMNARECQLPTGS2NISCHTSPO | |
| SCHEMBL6820932 | 0.92 | PTGS2 (0.52) | LMNARECQLPTGS2NISCHMAP2 | |
| SCHEMBL6825115 | 0.92 | NISCH (0.49) | LMNARECQLPTGS2NISCH | |
| Hydrochloric Acid SCHEMBL7736320 | 0.91 | NISCH (0.50) | LMNARECQLPTGS2NISCH | |
| Hydrochloric Acid SCHEMBL7735546 | 0.91 | PTGS2 (0.51) | LMNARECQLPTGS2NISCHMAP2 | |
| SCHEMBL6824382 | 0.89 | NISCH (0.54) | LMNARECQLPTGS2NISCHMAP2 | |
| SCHEMBL6826340 | 0.88 | PTGS2 (0.50) | LMNARECQLPTGS2NISCH | |
| Hydrochloric Acid SCHEMBL7736206 | 0.88 | NISCH (0.53) | LMNARECQLPTGS2NISCHMAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | TAKEUCHI KUMIKO (US) | 2004-01-15 | — | — | US | claimed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | claimed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | claimed |
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | TAKEUCHI KUMIKO (US) | 2004-01-15 | — | — | US | disclosed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | GPR119, IAPP, GLP1R | LMNA 3624/4885RECQL 1979/4885PTGS2 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.